September 17, 2021 5:23pm

Even as volatility jumps +11.34%

The Biostage (BSTG) Chronicles: Friday, 229 traded shares dropped the share price -$0.38 to $3.63 after Thursday’s -$0.04 with 461 shares traded, suddenly 14,641 were traded with the shares down -$0.04. Proves my facts of the “pump/promote” actions; why hasn’t the SEC questioned who or which entity is buying these shares – there is a definite pattern?

My comments try to distinguish the temporary from real pricing digression or progress with a 360-degree view.

Week in review …

The Dow closed DOWN -166.44 points (-0.48%); the S&P closed DOWN -40.76 points (-0.91%) while the Nasdaq closed DOWN -137.96 points (-0.91%)

 

Henry’omics:

Indexes closed sharply lower in a broad sell-off on Friday as investors remain cautious due to a resurgent Covid virus, negative news of a booster shot confused communication, a military drone strike that killed an innocent family; in addition to a potential shift in the Federal Reserve timetable (meeting next week), mixed economic data and a historical tendency for September to be a weak month for equities.

The Dow lost -0.1%, the S&P 500 fell -0.6% and the Nasdaq dived -0.5% this week.

For September, the Dow is down -2.2%, the S&P 500 -2% and the Nasdaq has lost 1.4%.

  • However, the stem, cell and gene therapy sector spiral up from a negative open, six (6) of twelve (12) and one (1) holiday of September sessions and being oversold.

Note: The FDA advisory committee on Friday rejected a plan to administer booster shots of Pfizer and BioNTech’s Covid-19 vaccine to the general public. Pfizer (PFE) fell 1.3% and BioNTech (BNTX) dropped 3.6%. Moderna (MRNA) lost 2.4%.

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:

  • Friday opened negative at 11/20, 3 flats and 1 acquired, flipped positive at the mid-day at 18/16 and 1 acquired, closing positive at 28/6 and 1 acquired;
  • Thursday opened negative at 8/25, 1 flat and 1 acquired, stayed negative at the mid-day at 12/21, 1 flat and 1 acquired, closing positive at 16/13, 5 flats and 1 acquired;
  • Wednesday opened positive at 19/13, 2 flats and 1 acquired, stayed positive at the mid-day at 21/12, 1 flat and 1 acquired, closing positive at 18/15, 2 flats and 1 acquired;
  • Tuesday opened positive at 25/7, 2 flats and 1 acquired, flipped negative at the mid-day to 9/23, 2 flats and 1 acquired, closing negative 5/29 and 1 acquired;
  • Monday opened negative at 10/22, 2 flats and 1 acquired, tripped positive at the mid-day at 19/15 and 1 acquired, ending with a negative close of 15/19 and 1 acquired

 

RegMed Investors’ (RMi) pre-open: “warned yesterday, caution today. Quadruple Witching will occur today during the final hour of stock market trading, stock index futures, stock index options, stock options, and single-stock futures expire” …  https://www.regmedinvestors.com/articles/12099

 

The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?” … https://www.regmedinvestors.com/articles/12087

 

Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542  … to date:

  • Net Income: 3 and Net losses: 23
  • Applied Genetic Technologies (AGTC) reports 9/23

 

Key Metric - volume:

  • Sector volume was HIGHER with 17 of the 28-upside having higher than the 3-month average volume with HIGH volume of 3 of 6-downside having higher than the 3-month average volume;

 

The Biostage (BSTG) Chronicles: WHAT happened to the usual “pump/promote”, Friday 129 shares traded dropping the share price -$0.38 after Thursday closed -$0.04 with 14,641 shares traded after Wednesday opened down -$0.04 (404 shares traded) and then promptly jumped +$0.52 with 17,107 shares traded after Tuesday closed down -$0.27 to $3.56 with 6,551 shares traded following Monday’s +$0.04 to $3.83 with 26,150 shares traded,

Last Fridays closed down -$0.19 to $3.79 with 22,124 shares traded after Thursday traded up +$0.66 to $3.98 with 6,0622 shares traded, Wednesday traded +$0.57 with 7,833 shares traded after last Tuesday closing down -$0.75 to $2.75 with 6,705 shares traded.

  • Today is establishes the fact of how BSTG’s share trades with and without the “push/promote”,
  • WHAT is BSTG’s value proposition, after all the share price “pumping”?
  • Is management responding to U.S./non-U.S./ Chinese investors complaints after the last (listed pricing) private placement of $4.71?
  • Where are these buying monies coming from?

 

There are clear winners and losers

Jumping with share pricing momentum:

  • CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), Intellia Therapeutics (NTLA) - again, Editas Medicine (EDIT) - again, Vericel (VCEL) to name 5 of the 28 inclining of the 35 covered

Hammered in today’s market:

  • ReNeuron (RENE.L), Biostage (BSTG), Mesoblast (MESO), Chinook Therapeutics (KDNY), Caladrius Biosciences (CLBS), Athersys (ATHX) to name 6 of the 6 declining of the 35 covered

Closing:

  • 1 – Stemline Therapeutics (STML) – acquired

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Friday, the IBB closed up +0.64% and XBI closed up +1.44%
  • Thursday, the IBB closed up +0.41% and XBI closed up +0.44%
  • Wednesday, the IBB closed up +1.10% and XBI closed up +1.12%
  • Tuesday, the IBB closed down -0.23% and XBI closed down -1.59%
  • Monday, the IBB closed down -1.68% and XBI closed down -0.49%

 

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Friday was up +2.12 points or +11.34% at 20.41
  • Thursday was up +0.51 points or +2.81% at 18.69
  • Wednesday was down -1.28 points or -6.58% at 18.18
  • Tuesday was up +0.10 points or +0.52% at 19.47
  • Monday was down -1.58 points or -7.54% at 19.37

 

September, the third month of Q3/21:

Friday closed positive with 28 advancers, 6 decliners and 1 acquired

Thursday closed positive with 16 advancers, 13 decliners, 5 flat and 1 acquired

Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired

Tuesday closed negative with 5 advancers, 29 decliners and 1 acquired

Monday (9/13) closed negative with 15 advancers, 19 decliners and 1 acquired

Friday closed negative with 7 advancers, 26 decliners, 1 flat and 1 acquired

Thursday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired

Wednesday closed negative with 7 advancers, 27 decliners and 1 acquired

Tuesday closed negative with 10 advancers, 22 decliners, 2 flats and 1 acquired

Monday was a holiday

Friday closed negative with 8 advancers, 26 decliners and 1 acquired

Thursday closed positive with 27 advancers, 5 decliners, 2 flat and 1 acquired

Wednesday closed positive with 20 advancers, 13 decliners, 1 flat and 1 acquired

 

 

The BOTTOM LINE: What more I can write, when you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started.

The stem, cell and gene therapy sector is vulnerable to what could be extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”

WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, the facts and truth need to be recognized!

 

Week in Review:

Pre-Open’s:

Monday: RegMed Investors’ (RMi) pre-open: the stem, cell and gene therapy sector’s still vulnerable … https://www.regmedinvestors.com/articles/12091

Tuesday: RegMed Investors’ (RMi) pre-open: the remaining Q3 cycle, treading water … https://www.regmedinvestors.com/articles/12093

Wednesday: RegMed Investors’ (RMi) pre-open: after six (6) negative of the last ten (10) sessions – a few buy maybes but, be cautionary and selective in moves … https://www.regmedinvestors.com/articles/12095

Thursday: RegMed Investors’ (RMi) pre-open: exit early, meaning today … https://www.regmedinvestors.com/articles/12097

Friday: RegMed Investors’ (RMi) pre-open: warned yesterday, caution today … https://www.regmedinvestors.com/articles/12099

 

Closing Bells:

Monday: RegMed Investors’ (RMi) closing bell: sector action, sputtering … https://www.regmedinvestors.com/articles/12092

Tuesday: RegMed Investors’ (RMi) closing bell: key word for today’s session – fragility … https://www.regmedinvestors.com/articles/12094

Wednesday: RegMed Investors’ (RMi) closing bell: follow the bouncing share pricings … https://www.regmedinvestors.com/articles/12096

Thursday: RegMed Investors’ (RMi) closing bell: the cell and gene therapy sector share pricing beat-back quadruple witching … https://www.regmedinvestors.com/articles/12098

Friday: RegMed Investors’ (RMi) closing bell: cell and gene therapy sector rebounds from the quadruple witching swallowing fear … https://www.regmedinvestors.com/articles/12100

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.